Europe Acute Lung Injury Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Therapy (Mechanical Ventilation, Fluid Management, Pharmacotherapy, and Adjunctive Procedures) and End User (Hospitals, Ambulatory Surgery Centers, and Others)
Market Introduction
The European acute lung injury market is divided into Germany, UK, France, Italy, Spain, and the rest of Europe. Germany led the market in 2021. Germany is much ahead in terms of the healthcare industry. It has the presence of market leaders from across the world. Also, there are well-established players across the country that is contributing to the overall healthcare industry, including diagnostics and treatment of acute lung injury. The use of e-cigarettes is associated with many patterns of lung injury, and as the use of these products continues to increase, these patterns have only recently been confirmed. For instance, according to National Center for Biotechnology Information, since 2001, the traditional smoking rate of adolescents between 14 and 17 years old in Germany has declined. The opposite trend of e-cigarette consumption can be observed. Trends such as “juuling” are attracting more attention from adolescents. The popularity is reflected in the numbers: Currently, 20.2% of young people aged 14-17 in Germany have used e-cigarettes. Although it is believed that the risk of exposure to potentially harmful components of e-cigarettes is significantly lower than that of combustible cigarettes, exposure to e-cigarette aerosols during adolescence and early adulthood is not without risks and may cause lung toxicity. Similarly, according to National Center for Biotechnology Information, the reported prevalence of ever-use of E-cigarette in Germany is 11.8%. Growing prevalence of respiratory diseases and surging technological advancements by market players are the major factor driving the growth of the Europe acute lung injury market.
In case of COVID-19, Spain, Italy, Germany, France, and the UK are among the most affected European countries. As per the Worldometer, as of September 16, 2021, Spain, UK, Italy, Germany, and France recorded 4,922,249; 7,312,683; 4,618,040; 4,117,263; and 6,926,604, respectively, COVID-19 cases, and the deaths toll is also high in these countries. In addition, Novel coronavirus-associated disease (COVID-19) was first detected in Spain on 31 January 2020, with more than 204 178 cases subsequently identified in 3 months.1 Severe COVID-19 is associated with high circulating levels of inflammatory cytokines akin to a cytokine release syndrome that frequently results in respiratory failure. To date, scant histopathological information of infected patients is available. Few descriptions of histopathological findings have mainly reported pneumonitis and diffuse alveolar damage (DAD).2–5 To advance in the knowledge of COVID-19-associated tissue damage is important to understand the mechanisms of damage caused by SARS-COV-2.
Get more information on this report :
Market Overview and Dynamics
The Europe acute lung injury market is expected to grow from US$ 156.55 million in 2021 to US$ 211.12 million by 2028; it is estimated to grow at a CAGR of 4.4% from 2021 to 2028. The degeneration of various cells or tissues with age leads to a greater risk of multiple diseases. Elderly people are more prone to get affected by the failure of organs such as the lungs, heart, and kidney. This is mainly ascribed to the changes in the composition and metabolic activities in the ecosystem of the aging human body. With the increasing age, the incidence of organ systems efficiency decreases resulting prone to diseases such as respiratory diseases and other infection, thereby driving the target market. Thus, ALI is correlated with increased morbidity and mortality in the aging population. Also, age is generally reported as a risk factor for the growth of ARDS. Along with developed countries such as UK, France, and Germany, developing countries are experiencing significant growth in the geriatric population. The population is aging; over 65s are expected to account for 1 in 6 of the population by 2050, increasing 1 in 11 in 2019. With a strong association between aging and increased incidence of diseases—including respiratory conditions such as chronic obstructive pulmonary disease and acute infection—thorough research on the impact of disease risk and severity will be necessary to manage the health of an ever-aging population effectively. The growth of the geriatric population in these countries is driven by improved healthcare facilities and better healthcare services, which has resulted in increased life expectancy. Thus, the growing aging population is among the major factors for the growth of the Europe acute lung injury market.
Key Market Segments
In terms of therapy, the mechanical ventilation segment accounted for the largest share of the Europe acute lung injury market in 2020. In terms of end user, the hospitals segment held a larger market share of the Europe acute lung injury market in 2020.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the Europe acute lung injury market are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Apeiron Biologics AG; APEPTICO Forschung und Entwicklung GmbH; GlaxoSmithKline Plc; Histocell; Stemedica Cell Technologies, Inc; and Windtree Therapeutics, Inc.
Reasons to buy report
- To understand the Europe acute lung injury market landscape and identify market segments that are most likely to guarantee a strong return
- Stay ahead of the race by comprehending the ever-changing competitive landscape for Europe acute lung injury market
- Efficiently plan M&A and partnership deals Europe acute lung injury market by identifying market segments with the most promising probable sales
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form Europe acute lung injury market
- Obtain market revenue forecast for market by various segments from 2021-2028 in Europe region.
Europe Acute Lung Injury Market Segmentation
Europe Acute Lung Injury Market - By Therapy
- Mechanical Ventilation
- Fluid Management
- Pharmacotherapy
- Adjunctive Procedures
Europe Acute Lung Injury Market - By End User
- Hospitals
- Ambulatory Surgery Centers
- Others
Europe Acute Lung Injury Market - By Country
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
Europe Acute Lung Injury Market - Company Profiles
- Apeiron Biologics AG
- APEPTICO Forschung und Entwicklung GmbH
- GlaxoSmithKline Plc
- Histocell
- Stemedica Cell Technologies, Inc
- Windtree Therapeutics, Inc.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Acute Lung Injury Market – By Therapy
1.3.2 Europe Acute Lung Injury Market – By End User
1.3.3 Europe Acute Lung Injury Market– By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Acute Lung Injury Market– Market Landscape
4.1 Overview
4.2 Europe PEST Analysis
4.3 Experts Opinion
5. Europe Acute Lung Injury Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Prevalence of Respiratory Diseases
5.1.2 Increasing Geriatric Population
5.2 Market Restraints
5.2.1 Overpriced Therapies
5.3 Market Opportunities
5.3.1 Surging Technological Advancements by Market Players
5.4 Future Trends
5.4.1 Escalating Pipeline Drugs
5.5 Impact Analysis
6. Acute Lung Injury Market– Europe Analysis
6.1 Europe Acute Lung Injury Market Revenue Forecast and Analysis
7. Europe Acute Lung Injury Market Analysis – By Therapy
7.1 Overview
7.2 Europe Acute Lung Injury Market Revenue Share, by Therapy (2021 and 2028)
7.3 Mechanical Ventilation
7.3.1 Overview
7.3.2 Mechanical Ventilation: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Fluid Management
7.4.1 Overview
7.4.2 Fluid Management: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Pharmacotherapy
7.5.1 Overview
7.5.2 Pharmacotherapy: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Adjunctive Procedures
7.6.1 Overview
7.6.2 Adjunctive Procedures: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
8. Europe Acute Lung Injury Market Analysis – By End User
8.1 Overview
8.2 Europe Acute Lung Injury Market Revenue Share, by End User (2021 and 2028)
8.3 Hospitals
8.3.1 Overview
8.3.2 Hospitals: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Ambulatory Surgery Centers
8.4.1 Overview
8.4.2 Ambulatory Surgery Centers: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
9. Europe Acute Lung Injury Market – Country Analysis
9.1 Europe: Acute Lung Injury Market
9.1.1 Overview
9.1.2 Europe: Acute Lung Injury Market, by Country, 2021 & 2028(%)
9.1.2.1 Germany: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.1.1 Germany: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.1.2 Germany: Acute Lung Injury Market, by Therapy, 2019–2028 (USD Million)
9.1.2.1.3 Germany: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)
9.1.2.2 France: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.2.1 France: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.2.2 France: Acute Lung Injury Market, by Therapy, 2019–2028 (USD Million)
9.1.2.2.3 France: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)
9.1.2.3 UK: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.3.1 UK: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.3.2 UK: Acute Lung Injury Market, by Therapy, 2019–2028 (USD Million)
9.1.2.3.3 UK: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)
9.1.2.4 Italy: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.4.1 Italy: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.4.2 Italy: Acute Lung Injury Market, by Therapy, 2019–2028 (USD Million)
9.1.2.4.3 Italy: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)
9.1.2.5 Spain: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.5.1 Spain: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.5.2 Spain: Acute Lung Injury Market, by Therapy, 2019–2028 (USD Million)
9.1.2.5.3 Spain: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)
9.1.2.6 Rest of Europe: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.6.1 Rest of Europe: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.6.2 Rest of Europe: Acute Lung Injury Market, by Therapy, 2019–2028 (USD Million)
9.1.2.6.3 Rest of Europe: Acute Lung Injury Market, by End User, 2019–2028 (USD Million)
10. Impact Of COVID-19 Pandemic on Europe Acute Lung Injury Market
10.1 Europe: Impact Assessment of COVID-19 Pandemic
11. Industry Landscape
11.1 Overview
11.2 Organic Developments
11.2.1 Overview
11.3 Inorganic Developments
11.3.1 Overview
12. Company Profiles
12.1 GlaxoSmithKline Plc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Stemedica Cell Technologies, Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Histocell
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 APEPTICO Forschung und Entwicklung GmbH
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Windtree Therapeutics, Inc.
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Apeiron Biologics AG
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. Europe Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
Table 2. Germany: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)
Table 3. Germany: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 4. France: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)
Table 5. France: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 6. UK: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)
Table 7. UK: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 8. Italy: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)
Table 9. Italy: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 10. Spain: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)
Table 11. Spain: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 12. Rest of Europe: Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)
Table 13. Rest of Europe: Acute Lung Injury Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 14. Organic Developments Done by Companies
Table 15. Inorganic Developments Done by Companies
Table 16. Glossary of Terms
LIST OF FIGURES
Figure 1. Europe Acute Lung Injury Market Segmentation
Figure 2. Europe Acute Lung Injury Market Segmentation, By Country
Figure 3. Europe Acute Lung Injury Market Overview
Figure 4. Mechanical Ventilation Segment Held the Largest Share of the Market in 2021
Figure 5. The UK to Show Significant Growth During Forecast Period
Figure 6. Europe and PEST Analysis
Figure 7. Europe Acute Lung Injury Market Impact Analysis of Driver and Restraints
Figure 8. Europe Acute Lung Injury Market– Revenue Forecast and Analysis
Figure 9. Europe Acute Lung Injury Market Revenue Share, by Therapy (2021 and 2028)
Figure 10. Europe Mechanical Ventilation: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
Figure 11. Europe Fluid Management: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Europe Pharmacotherapy: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Europe Adjunctive Procedures: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Europe Acute Lung Injury Market Revenue Share, by End User (2021 and 2028)
Figure 15. Europe Hospitals: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. Europe Ambulatory Surgery Centers: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. Europe Others: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. Europe: Acute Lung Injury Market, by Key Country – Revenue (2021) (USD Million)
Figure 19. Europe: Acute Lung Injury Market, by Country, 2021 & 2028 (%)
Figure 20. Germany: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
Figure 21. France: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
Figure 22. UK: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
Figure 23. Italy: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
Figure 24. Spain: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
Figure 25. Rest of Europe: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
Figure 26. Impact of COVID-19 Pandemic in European Country Markets
- Apeiron Biologics AG
- APEPTICO Forschung und Entwicklung GmbH
- GlaxoSmithKline Plc
- Histocell
- Stemedica Cell Technologies, Inc
- Windtree Therapeutics, Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe acute lung injury market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the Europe acute lung injury market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the acute lung injury market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution